Information från ABG Sundal Collier

Här finner du information kring börsens mindre och medelstora bolag. Avsändare är ABG Sundal Collier, innehållet är inte skapat av placera.nu:s redaktion.

« Tillbaka

Midsona - Sales miss on volume but margin held up

22 oktober 2026

<a id="bm-comp-32d217dd-67a6-4f45-80d2-f708979760f8" name="bm-comp-32d217dd-67a6-4f45-80d2-f708979760f8" class="BMCustomAnchor"></a><table><tr><td bm-component-id="32d217dd-67a6-4f45-80d2-f708979760f8" style="vertical-align: top; width:100.000000%;"><ul><li>Adj. EBITA SEK 57m, 6% below ABGSCe SEK 61m</li><li>Organic growth softer than expected</li><li>Consensus adj. EBITA revisions likely down l.s.d</li></ul></td></tr></table><a id="bm-comp-61546ac4-ae66-476c-aa1a-e53d8f27a92d" name="bm-comp-61546ac4-ae66-476c-aa1a-e53d8f27a92d" class="BMCustomAnchor"></a><table><tr><td bm-component-id="61546ac4-ae66-476c-aa1a-e53d8f27a92d" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">Top-line miss, margin held up by mix</h3><p>The Q3 report was below expectations on sales and adj. EBITA. However, it was better than expected on EPS due to positive net financials. Sales were SEK 910m (-4% vs ABGSCe 948m), for y-o-y growth of 1.7% (-4.3pp vs ABGSCe 5.9%). Organic growth was -3.7% (-4.9pp vs ABGSCe 1.2%), with Risenta adding 4.5% and FX 0.9%. Own consumer brands were -0.2% org., licenced brands -2% and contract manufacturing -11%. By division, Nordics sales were SEK 607m (5.3% y-o-y, org. -3.0%) with own consumer brands +2% org. but contract manufacturing -45% on terminated low-margin contracts. North Europe was the weak link at SEK 212m (org. -10%), where own consumer brands fell 17% org. on delistings at a large grocery customer and the summer heatwave. South Europe grew 10% org. on light fire-hit comps. The adj. GM was the bright spot at 29% (1.0pp above ABGSCe), driven by mix (higher share of own brands) and complexity reduction, partly offset by higher transport and packaging costs not yet passed on. Adj. EBITA came in at SEK 57m, 6% below estimates, but the margin of 5% was in line with ABGSCe. The EPS beat of 27% was mainly due to an FX translation gain of 9m.</p><h3 class="bm-h3">Strategy review widens</h3><p>The CEO states the quarter &#8220;did not live up to our ambitions&#8221;. R12M organic growth is -1.3% and the adj. EBIT margin 4.3%, against the 2027 targets of 3-5% and &gt;8%. Management is deepening the brand portfolio review, with capital and marketing to be concentrated on fewer differentiated brands. In North Europe, the fix is a stronger offering plus &#8220;cost adjustments&#8221;; in consumer health, management concedes execution has been too slow. Spain is to be made profitable in a smaller format without rebuilding lost capacity, while &#8220;more transformative alternatives&#8221; are being evaluated. Marketing spend on priority brands will continue to weigh on near-term margins, and input cost increases (transport, packaging, drought-hit raw materials) have not yet been pushed through to customers.</p><h3 class="bm-h3">Estimate revisions likely minor, but negative</h3><p>The share had a very strong start to the year, reaching SEK 15 in July but has been soft since the Q2 report, dropping ~13% in the last 90 days. Midsona is trading at ~7x NTM EV/EBITA on our unrevised estimates. Our initial understanding of the report as well as a mechanical calculation suggest that consensus' adj. EBITA estimates for '26e-'28e could be negative within a low-single-digit range. The company will host a presentation of the Q3 report at CET 11.00 (<a data-bm-trackable="false" href="https://events.inderes.com/midsona/q3-report-2026" target="_blank">link</a>).</p><table id="bm-img-e51caad1-b7a5-42e1-ba1b-99666c42ed5a" class="bm-img-table xslt-img-empty xslt-img-include"><tr><td class="xslt-img-caption">Deviation table</td></tr><tr><td><img bm-img-encrypt="e51caad1-b7a5-42e1-ba1b-99666c42ed5a" bm-img-original-height="428" bm-img-original-width="567" bm-img-svg="image:image_upload/99719_a10a30c6-e45a-4504-868e-99cbad9fd68a.svg" bm-img-width-hint="77.99%" id="bm-id-e51caad1-b7a5-42e1-ba1b-99666c42ed5a" src="https://abgsc.bluematrix.com/images/image_upload/99719_a10a30c6-e45a-4504-868e-99cbad9fd68a_567.png" svg="/nas/web/clients/abgsc/images/image_upload/99719_a10a30c6-e45a-4504-868e-99cbad9fd68a.svg" width="567" alt="" title="" /></td></tr><tr><td class="xslt-img-source">Source: ABG Sundal Collier, company data</td></tr></table></td></tr></table>

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-10-22 Ework Group - Moving in the right direction Ework Group Analys
2026-10-22 Svedbergs Group - UK margin recovery delayed Svedbergs G.. Analys
2026-10-22 Midsona - Volume recovery taking its time Midsona Analys
2026-10-22 Careium - Scaling as promised Careium Analys
2026-10-22 Coor - A cleaner path to growth Coor Analys
2026-10-22 Proact - Positive organic growth in 2027e looks l... Proact Analys
2026-10-22 Eastnine - The Bridge now in the books Eastnine Analys
2026-10-22 Fastpartner - Solid Q3 numbers with improving occ... Fastpartner Analys
2026-10-22 Impact Coatings - Positive EBIT as systems return Impact Coat.. Analys
2026-10-22 Proact - Q3 beat driven by gross margin and opex Proact Analys
2026-10-22 Ework Group - Order intake decreasing, but a beat... Ework Group Analys
2026-10-22 Midsona - Sales miss on volume but margin held up Midsona Analys
2026-10-22 Coor - Small steps in the right direction Coor Analys
2026-10-22 Svedbergs Group - Q3 EBITA -4% vs cons. on softer UK Svedbergs G.. Analys
2026-10-22 Careium - A clean beat with no asterisks Careium Analys
2026-10-21 Ovzon - Orders starting to pile up Ovzon Analys
2026-10-21 Eltel - Contract wins improve growth visibility Eltel Analys
2026-10-21 Nolato - Organic acceleration and M&A comeback Nolato Analys
2026-10-21 Impact Coatings - Systems back, metals drive beat Impact Coat.. Analys
2026-10-21 Ovzon - Better EBIT on lower opex Ovzon Analys